Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLM Apollomics	$5.45 -7.8%	$6.15	$4.47 ▼ $35.98	$6.52M	0.92	50,183 shs	10,891 shs
BDRX Biodexa Pharmaceuticals	$7.04	$8.69	$5.85 ▼ $163.10	$4.36M	0.98	35,712 shs	8,702 shs
MIRA MIRA Pharmaceuticals	$1.50 +2.0%	$1.42	$0.73 ▼ $2.70	$28.03M	1.77	561,375 shs	272,804 shs
NNVC NanoViricides	$1.50 +2.0%	$1.51	$0.94 ▼ $2.34	$24.11M	0.96	244,988 shs	119,872 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLM Apollomics	-7.86%	-4.05%	-9.32%	+4.99%	-59.36%
BDRX Biodexa Pharmaceuticals	0.00%	-1.26%	-16.19%	-45.00%	+703,999,900.00%
MIRA MIRA Pharmaceuticals	+2.04%	+8.70%	-19.79%	+3.45%	-22.28%
NNVC NanoViricides	+2.04%	-5.06%	-6.25%	+6.38%	-21.47%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Earnings & Valuation
APLM Apollomics	0.4362 of 5 stars	0.0	3.0	3.3	0.0
BDRX Biodexa Pharmaceuticals	1.0264 of 5 stars	0.0	5.0	3.6	0.0
MIRA MIRA Pharmaceuticals	3.2629 of 5 stars	3.8	5.0	3.3	0.6
NNVC NanoViricides	0.3133 of 5 stars	0.0	5.0	0.6	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLM Apollomics	0.00	N/A	N/A	N/A
BDRX Biodexa Pharmaceuticals	0.00	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	3.50	Strong Buy	$17.00	1,033.33% Upside
NNVC NanoViricides	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLM Apollomics	$1.49M	4.02	N/A	N/A	$4.48 per share	1.22
BDRX Biodexa Pharmaceuticals	$470K	9.29	N/A	N/A	$2.91 per share	2.42
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	$0.13 per share	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	$0.66 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLM Apollomics	-$53.86M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
BDRX Biodexa Pharmaceuticals	-$7.32M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	-$7.85M	-$0.51	N/A	N/A	N/A	N/A	-329.63%	-271.22%	N/A
NNVC NanoViricides	-$8.29M	-$0.70	N/A	∞	N/A	N/A	-87.90%	-78.69%	N/A

Latest APLM, BDRX, MIRA, and NNVC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2025	Q2 2025	MIRA MIRA Pharmaceuticals	-$0.11	-$0.09	+$0.02	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
BDRX Biodexa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MIRA MIRA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NNVC NanoViricides	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLM Apollomics	N/A	1.39	1.39
BDRX Biodexa Pharmaceuticals	0.01	1.75	1.75
MIRA MIRA Pharmaceuticals	N/A	12.86	12.86
NNVC NanoViricides	N/A	3.44	2.47

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLM Apollomics	19.13%
BDRX Biodexa Pharmaceuticals	17.51%
MIRA MIRA Pharmaceuticals	35.16%
NNVC NanoViricides	10.30%

Insider Ownership

Company	Insider Ownership
APLM Apollomics	N/A
BDRX Biodexa Pharmaceuticals	0.34%
MIRA MIRA Pharmaceuticals	6.65%
NNVC NanoViricides	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLM Apollomics	45	1.10 million	N/A	Not Optionable
BDRX Biodexa Pharmaceuticals	20	620,000	3.64 million	Not Optionable
MIRA MIRA Pharmaceuticals	2	19.07 million	17.80 million	Not Optionable
NNVC NanoViricides	20	16.07 million	14.92 million	Optionable

APLM, BDRX, MIRA, and NNVC Headlines

Recent News About These Companies

NanoViricides says antiviral candidate NV-387 could address global measles surge

July 30, 2025 | proactiveinvestors.com

Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides

July 30, 2025 | accessnewswire.comA

NanoViricides eyes revenue opportunities with broad-spectrum antiviral NV-387

July 23, 2025 | proactiveinvestors.com

NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value

July 23, 2025 | accessnewswire.comA

Measles Now Has a Drug – NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

July 21, 2025 | usatoday.com

NanoViricides says lead antiviral boosted survival in measles-infected mice

July 21, 2025 | proactiveinvestors.com

Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides

July 21, 2025 | accessnewswire.comA

NanoViricides designs trial protocol for phase II MPox Clade Ia with a novel drug NV-387 for treating MPox disease

July 18, 2025 | pharmabiz.comP

WHO Extended Global Emergency Status of MPox Epidemic – Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

July 16, 2025 | azcentral.comA

NanoViricides says MPox drug candidate NV-387 poised for Phase II trial as WHO extends global health emergency

July 16, 2025 | proactiveinvestors.com

WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides

July 16, 2025 | accessnewswire.comA

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks

July 15, 2025 | proactiveinvestors.com

NanoViricides positioned at forefront of Mpox treatment efforts, says Zacks

July 15, 2025 | proactiveinvestors.com

NNVC: NanoViricides Set to Initiate Phase 2 Trial in MPox

July 15, 2025 | finance.yahoo.com

NanoViricides nears completion of clinical trial design for MPox treatment

July 14, 2025 | proactiveinvestors.com

Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides

July 14, 2025 | markets.businessinsider.com

NanoViricides (NNVC) Accelerates MPox Drug Development, Citing Strong Business and Public Health Case

July 7, 2025 | theglobeandmail.com

NanoViricides advances antiviral candidate NV-387 into Phase 2 trials for Mpox

July 2, 2025 | proactiveinvestors.com

NanoViricides Inc.

June 19, 2025 | barrons.com

NanoViricides touts antiviral NV-387 as tool against new COVID variant

June 18, 2025 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

APLM, BDRX, MIRA, and NNVC Company Descriptions

Apollomics NASDAQ:APLM

$5.45 -0.46 (-7.78%)

Closing price 08/15/2025 03:55 PM Eastern

Extended Trading

$5.59 +0.14 (+2.57%)

As of 08/15/2025 04:31 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Biodexa Pharmaceuticals NASDAQ:BDRX

$7.04 0.00 (0.00%)

Closing price 08/15/2025 03:59 PM Eastern

Extended Trading

$7.04 0.00 (0.00%)

As of 08/15/2025 07:51 PM Eastern

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

MIRA Pharmaceuticals NASDAQ:MIRA

$1.50 +0.03 (+2.04%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.02 (-1.33%)

As of 08/15/2025 07:59 PM Eastern

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

NanoViricides NYSE:NNVC

$1.50 +0.03 (+2.04%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.48 -0.02 (-1.33%)

As of 08/15/2025 07:35 PM Eastern

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time